New dried blood spot kit could make large-scale longevity and disease research easier, cheaper and more inclusive.
One of the biggest barriers to large-scale health research has been getting people to show up for blood tests.
Whether researchers are studying Alzheimer’s disease, chronic inflammation or the biological changes associated with aging, collecting samples typically requires participants to visit clinics, schedule appointments and undergo traditional blood draws. That process is expensive, time-consuming and often limits who can take part.
Now, California-based Alamar Biosciences has unveiled a new tool designed to change that equation. The company has launched its NULISA Dried Blood Spot (DBS) Extraction Kit, allowing researchers to analyze proteins from small blood samples collected at home through a simple fingerstick [1]. Instead of requiring a vial of blood drawn from a vein, participants can provide just a few drops, dry the sample and ship it through standard mail.
At first glance, collecting blood from home is not a new idea. Dried blood spot testing has existed for decades. The challenge has always been what happens next.
Scientists increasingly rely on proteomics, the study of proteins circulating throughout the body, to understand disease risk and biological aging. Many of the most valuable protein signals exist in extremely small quantities, making them difficult to detect in tiny blood samples. Historically, researchers often had to choose between convenience and sensitivity.
According to Alamar, its new workflow bridges that gap by enabling researchers to recover and analyze protein signals from home-collected dried blood samples without losing much of the biological information they are seeking.
In validation studies, the company reported 85% to 95% target detectability across its neurology and inflammation-focused protein panels.
A shift toward decentralized research
The broader significance may lie in what the tech enables. Long-term studies frequently struggle to collect samples consistently over months or years. Participants move, miss appointments or live far from research centers. Those limitations can make it difficult to build the large datasets needed to understand how diseases develop or how aging unfolds over time. Home collection changes that dynamic.
Instead of asking participants to travel repeatedly to clinics, researchers can collect samples remotely, potentially capturing a much richer picture of how biology changes throughout daily life.
“This launch reflects our commitment to making proteomics more accessible for population-based screening programs,” said Dr Yuling Luo, founder, CEO and chair of Alamar. “By combining the NULISA platform’s attomolar sensitivity with a standardized extraction workflow for microsamples, we are empowering researchers to unlock high-quality multiplexed proteomic data from remotely collected samples that were previously out of reach.”
The new kit is designed to work with several existing microsampling systems, including devices from Capitainer, Telimmune, Mitra and Tasso, making it easier for research groups to incorporate into ongoing studies.
The longevity opportunity
The implications for the longevity field could be significant. As researchers search for reliable biomarkers of aging, they increasingly need data from large and diverse populations rather than snapshots collected during occasional clinic visits.
Understanding how biological age changes in response to interventions, lifestyle shifts or emerging therapeutics may ultimately require frequent sampling at scale. That vision has often collided with practical reality. Traditional blood collection simply does not lend itself to regular monitoring across thousands of participants.
Remote sampling could help close that gap. The ability to collect high-quality biological data from home may allow researchers to track inflammation, neurodegeneration and other aging-related processes more continuously, while reducing the logistical burden on participants.
Dr Amanda Heslegrave, UCL, UK DRI, co-lead Biomarker Factory, described the capability as potentially transformative.
“The ability to generate high-quality proteomic data from a fingerstick blood sample is a transformative capability for population studies and longitudinal research,” she said. “A standardized extraction workflow like the NULISA DBS Extraction Kit makes it practical to integrate microsampling into remote collection protocols without sacrificing sensitivity or reproducibility.”
From the clinic to the living room
The longevity sector has spent years moving diagnostics closer to consumers, from wearable sensors to at-home testing kits. Alamar’s latest launch represents another step in that progression.
The immediate customers may be research institutions rather than consumers, but the direction of travel is clear: health data collection is steadily moving beyond hospitals and laboratories.
If researchers can reliably capture sophisticated biological information from a few drops of blood collected at home, the next generation of aging studies may look larger, more continuous and far more representative of the populations they aim to serve – which is very different from the last.
